SynthesisJournal of neurology2026
Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Very late-onset myasthenia gravis: a systematic review and meta-analysis of clinical severity and long-term outcomes.European geriatric medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe compared very late-onset myasthenia gravis (vloMG; onset ≥ 65 years) with MG beginning before age 65 years (non-vloMG) and contextualized these findings using the conventional early-onset (< 50 years, EOMG) versus late-onset (≥ 50 years, LOMG) classification.
methodsMEDLINE, Embase, CENTRAL and Google Scholar were searched from inception through May 2026. Odds ratios (ORs) and 95% confidence intervals were pooled by age group for sex, AChR and MuSK antibody positivity, double-seronegativity, thymoma and thymic hyperplasia.
resultsEight studies were included. Compared with non-vloMG, vloMG showed higher AChR-antibody positivity (OR, 3.08; 2.23-4.26) and lower double-seronegativity (OR, 0.34; 0.24-0.48) and thymoma prevalence (OR, 0.25; 0.18-0.35). Pooled estimates suggested lower MuSK-antibody positivity (OR, 0.50; 0.26-0.98) and thymic hyperplasia prevalence (OR, 0.22; 0.03-1.66), although these associations did not meet the multiplicity-adjusted significance threshold. Female prevalence did not differ significantly (OR, 0.77; 0.54-1.09). Compared with EOMG, LOMG showed lower female (OR, 0.32; 0.18-0.56) and thymic hyperplasia prevalence (OR, 0.45; 0.33-0.62). AChR-antibody positivity (OR, 1.68; 1.16-2.45), MuSK-antibody positivity (OR, 0.59; 0.35-0.97), double-seronegativity (OR, 0.64; 0.41-0.99) and thymoma prevalence (OR, 0.48; 0.29-0.80) did not meet the multiplicity-adjusted significance threshold. Exploratory analysis showed higher titin-antibody positivity in LOMG (OR, 10.00; 3.03-33.33). DISCUSSION: Advancing age at MG onset was associated with progressive enrichment of AChR-positive disease and declining MuSK positivity, seronegativity, and thymic pathology. These findings support subdivision into EOMG, intermediate-onset MG (50-64 years, IOMG) and vloMG.
Indexed as
Identifiers
42461294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.